These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 29508763)

  • 21. Immune checkpoint inhibition in malignant mesothelioma: Does it have a future?
    Mansfield AS
    Lung Cancer; 2017 Mar; 105():49-51. PubMed ID: 28089229
    [No Abstract]   [Full Text] [Related]  

  • 22. [Malignant pleural mesothelioma: 2013 state of the art].
    Campbell K; Brosseau S; Reviron-Rabec L; Bergot E; Lechapt E; Levallet G; Zalcman G
    Bull Cancer; 2013 Dec; 100(12):1283-93. PubMed ID: 24225007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP.
    Dubois F; Bazille C; Levallet J; Maille E; Brosseau S; Madelaine J; Bergot E; Zalcman G; Levallet G
    Target Oncol; 2022 Jul; 17(4):407-431. PubMed ID: 35906513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma.
    Nowak AK; Cook AM; McDonnell AM; Millward MJ; Creaney J; Francis RJ; Hasani A; Segal A; Musk AW; Turlach BA; McCoy MJ; Robinson BW; Lake RA
    Ann Oncol; 2015 Dec; 26(12):2483-90. PubMed ID: 26386124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study.
    Van den Bossche J; De Laere M; Deschepper K; Germonpré P; Valcke Y; Lamont J; Stein B; Van Camp K; Germonpré C; Nijs G; Roelant E; Anguille S; Lion E; Berneman Z
    PLoS One; 2024; 19(7):e0307204. PubMed ID: 39008481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
    Ceresoli GL; Aerts JG; Dziadziuszko R; Ramlau R; Cedres S; van Meerbeeck JP; Mencoboni M; Planchard D; Chella A; Crinò L; Krzakowski M; Rüssel J; Maconi A; Gianoncelli L; Grosso F
    Lancet Oncol; 2019 Dec; 20(12):1702-1709. PubMed ID: 31628016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemotherapy increases CDA expression and sensitizes malignant pleural mesothelioma cells to capecitabine treatment.
    Karatkevich D; Losmanova T; Zens P; Deng H; Dubey C; Zhang T; Casty C; Gao Y; Neppl C; Berezowska S; Wang W; Peng RW; Schmid RA; Dorn P; Marti TM
    Sci Rep; 2024 Aug; 14(1):18206. PubMed ID: 39107509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma.
    Chia PL; Russell PA; Scott AM; John T
    Expert Rev Anticancer Ther; 2016 Dec; 16(12):1235-1245. PubMed ID: 27696931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A catalogue of treatment and technologies for malignant pleural mesothelioma.
    Schunselaar LM; Quispel-Janssen JM; Neefjes JJ; Baas P
    Expert Rev Anticancer Ther; 2016; 16(4):455-63. PubMed ID: 26943000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma.
    Metaxas Y; Rivalland G; Mauti LA; Klingbiel D; Kao S; Schmid S; Nowak AK; Gautschi O; Bartnick T; Hughes BG; Bouchaab H; Rothschild SI; Pavlakis N; Wolleb S; Petrausch U; O'Byrne K; Froesch P; Löffler-Baumann M; Pratsch-Peter S; Russell P; Mingrone W; Savic S; Thapa B; Früh M; Pless M; von Moos R; John T
    J Thorac Oncol; 2018 Nov; 13(11):1784-1791. PubMed ID: 30142389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma.
    Zhang D; Liang J; Lv Y; Huang X; Guo W
    Medicine (Baltimore); 2022 Dec; 101(52):e32459. PubMed ID: 36596035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
    Chen D; Li X; Zhao H; Fu Y; Yao F; Hu J; Du N
    Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic treatment of malignant pleural mesothelioma.
    Grosso F; Scagliotti GV
    Future Oncol; 2012 Mar; 8(3):293-305. PubMed ID: 22409465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
    Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
    Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?
    Borea F; Franczak MA; Garcia M; Perrino M; Cordua N; Smolenski RT; Peters GJ; Dziadziuszko R; Santoro A; Zucali PA; Giovannetti E
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma.
    Mairinger FD; Vollbrecht C; Flom E; Christoph DC; Schmid KW; Kollmeier J; Popper HH; Mairinger T; Walter RFH
    Oncotarget; 2017 Jun; 8(23):37502-37510. PubMed ID: 28415584
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Evolving Therapeutic Landscape for Malignant Pleural Mesothelioma.
    Perera ND; Mansfield AS
    Curr Oncol Rep; 2022 Nov; 24(11):1413-1423. PubMed ID: 35657483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes.
    Buikhuisen WA; Scharpfenecker M; Griffioen AW; Korse CM; van Tinteren H; Baas P
    J Thorac Oncol; 2016 May; 11(5):758-768. PubMed ID: 26845191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
    Tsao A; Nakano T; Nowak AK; Popat S; Scagliotti GV; Heymach J
    Semin Oncol; 2019 Apr; 46(2):145-154. PubMed ID: 31280996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges.
    Ceresoli GL; Bonomi M; Sauta MG
    Expert Rev Anticancer Ther; 2016 Jul; 16(7):673-5. PubMed ID: 27224058
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.